Excludes commercially oriented and general research carried out or funded by private business, the costs of which are assumed to be included in the prices charged for the goods and services (e.g. medications that have been developed and/or supported by research activities).
100 × (Numerator ÷ Denominator)
Health research and experimental development expenditure
Numerator data elements:
Total recurrent health expenditure
Denominator data elements:
Disaggregation data elements:
Specified disaggregation: State/territory.
Available disaggregation: State/territory.
2008-09 data will be available in September 2010.
Most recent data available for 2010 CRC baseline report: 2007-08.
Specification: Long-term No further data development planned.
Other issues caveats:
Consider scope issues including looking at previous work by Rebecca James, and CSIRO workshop 2008. Also cross refer to activity-based funding (ABF) work on estimated research and development expenditure in hospitals.